UNSPSC 51112701: Carboplatin

This classification denotes a platinum compound with the molecular formula C6H6O4.Pt.2H3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BG3F62OND5, chemically known as cis-diammine(1,1-cyclobutanedicarboxylato) platinum but more generally known as carboplatin, which bears US NIH Compound Identifier 38904. European Medicines Agency schedules Carboplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06614MIG.

UNSPSC 51112701 Carboplatin is a Commodity code covering the procurement of carboplatin, a chemotherapy drug used in cancer treatment by state and local health systems, correctional facilities, and public hospitals. State and local governments purchase carboplatin primarily through established pharmaceutical supply contracts, group purchasing organizations, and cooperative purchasing vehicles rather than direct solicitation. The drug is typically procured as part of broader oncology medication portfolios or within standing agreements with pharmaceutical distributors and healthcare supply vendors, often leveraging state Medicaid programs, group purchasing volume agreements, or correctional healthcare contracts to manage costs.

The source provides no recent state or local contract opportunities explicitly tagged to UNSPSC 51112701 Carboplatin. Procurement activity under this code is characterized by standing supply agreements and routine reorders through established pharmaceutical distribution channels rather than time-bound solicitations with published response dates. State and local entities sourcing carboplatin typically work through GPO contracts, state pharmaceutical cooperative purchasing programs, or direct relationships with licensed pharmaceutical wholesalers, making individual procurement actions less visible in posted RFP, RFQ, IFB, or ITB notice streams. Pursuit of this code may require relationship development with state purchasing offices, correctional healthcare administrators, and public hospital pharmacy directors rather than monitoring solicitation boards for discrete opportunities.